We have also demonstrated that AMPK in the para-tumor tissue plays a dominant role, as assessed in orthotopic allografts, to such an extent that even AMPK-null HCC can be effectively suppressed by aldometanib, as long as AMPK is present in the host tissue. This evidence concerns the gene PRKAA1 and hepatocellular carcinoma.